Pressure BioSciences (OTCQB:PBIO) and LEAP Technologies Monday signed a strategic co-development, co-marketing, and co-selling agreement, they said.
Under the agreement, the companies plan to develop a next generation
sample preparation system by combining PBI’s patented pressure cycling
technology (PCT) platform with LEAP’s proprietary robotics and lab
The companies share an industry focus in proteomics sample
preparation, primarily in mass spectrometry, an analytical technique
used to determine the characteristics of molecules.
PBI and LEAP believe that by combining the best attributes of both
technology platforms, they can develop a sample preparation system
"superior in quality and robustness" to current methods.
Proteomics is the study of the structure and function of proteins,
which has provided new and important insights into human health, and has
resulted in a better understanding of diagnosis, prognosis, and
possible cures of various diseases.
Automated sample preparation methods increase the precision and
quality of laboratory testing, which in-turn lifts the probability of
discovery. To that end, increased discovery leads to the development of
new and improved vaccines, therapeutics and diagnostics.
President and CEO of Pressure BioSciences,
Richard T. Schumacher, told Proactive Investors: "LEAP is an important
player in the robotics/lab automation area, especially in mass
spectrometry sample preparation workflow. This is a marriage made in
"We make a great team, as they have proprietary equipment/software
and we have instrumentation based on patented, game-changing technology.
This is the beginning of what we believe will be a long and
LEAP Technologies has been providing proprietary robotics and
laboratory automation equipment and support for specific applications
for over 20 years.
meanwhile, is focused on the development, marketing, and sale of
proprietary laboratory instrumentation and associated consumables based
on its PCT platform.
The platform uses rapid and repeating cycles of hydrostatic pressure
at controlled temperatures to extract cell components in the preparation
of a biological sample, such as DNA and proteins from humans, animals
and plants, for further study.
The applications of the company's PCT-based products are endless -
from the key $2 billion target market of mass spectrometry, to biomarker
discovery, forensics and counter-bioterrorism, among other uses.
CEO of LEAP Technologies, Werner Martin, said: "PCT is a powerful and
enabling technology platform. Because of its clear advantages, mass
spectrometry laboratories have begun to integrate PCT into their
standard sample preparation workflow, even though the PCT method has not
yet been fully automated.
"This has created a wonderful opportunity for us to partner with Pressure BioSciences, as we have the experience and expertise to bring automation to their patented PCT Platform."
"Over the past 20 years, we have developed a strong reputation in
robotics and laboratory automation while working with many of the
leading life sciences companies in the world, such as Waters Corporation
and Agilent Technologies.
"With a growing need for automation, we look forward to developing,
marketing, and selling the next generation sample preparation system for
proteomics with our colleagues at PBI."
Since Pressure BioSciences
began commercial operations in the middle of 2007, it has come a long
way, releasing a number of PCT-based products geared towards the $6
billion sample preparation market, including three pressure-generating
instruments named Barocyclers, a patent-pending sample homogenization
device (The Shredder SG3), five types of single-use processing
containers and six different, application-specific reagent kits.
Late last month, the company signed expanded technology license and
supply agreements with Target Discovery Inc, giving Target the right to
use its PCT platform for a planned entry into the clinical diagnostics